Clin2
NCT07385287Possibly a fitRecruiting

Malaria vaccine trial for healthy adults in Burkina Faso

Malaria (Plasmodium Falciparum)

Part of Infections clinical trials.

This study tests a new malaria vaccine called PfSPZ-LARC2 in healthy adults living in Burkina Faso. If you qualify, the vaccine is given to see if it can protect you from malaria.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
180 people
Ages
18 years to 50 years
Study type
Interventional

Who can take part

  • You are a healthy adult between 18 and 50 years old.
  • You must live in the study area and be willing to stay there for the whole study.
  • You cannot be pregnant, nursing, or planning to become pregnant during the study.
  • You must agree to avoid taking any other malaria medicines or participating in other trials.
  • You must be willing to take all study medications and follow the visit schedule.
  • You must pass a simple test to show you understand what the study involves.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07730177Not yet recruiting· Phase 1
Malaria vaccine trial for healthy adults in Burkina Faso

This study tests a new malaria vaccine called PfSPZ-LARC2 in healthy adults. Participants will receive the vaccine and then be exposed to malaria to see if it protects them.

Ouagadougou
NCT07675785Recruiting· Phase 2
Malaria Vaccine Study for Women Who Could Become Pregnant in Mali

This study tests an experimental malaria vaccine called PfSPZ-LARC2. Researchers want to learn if it is safe and effective for women who could become pregnant, especially in Mali where malaria is common. You would receive several doses of the vaccine and be followed for a few months.

Bamako
NCT07558122Not yet recruiting· Phase 1
Testing a new malaria vaccine in healthy adults

This study tests an experimental malaria vaccine (CVD 36000) in healthy volunteers aged 18–50. Researchers will give you the vaccine and later expose you to malaria parasites in a controlled setting to see if the vaccine protects you. This helps develop a safer vaccine for people in malaria-prone countries.

Baltimore, Maryland
NCT07548021Not yet recruiting· Phase 1
Safety study of MMV371 injection for malaria prevention

This study tests a new long-acting malaria prevention injection (MMV371) in healthy adults and adolescents in Rwanda. Researchers will monitor how safe it is and how your body processes it over 24 weeks.

Kigali
NCT05790889Recruiting· Phase 1/Phase 2
Study of an experimental malaria vaccine in babies in Burkina Faso

This Phase 1/2 study tests a new vaccine meant to protect young children against malaria. If you qualify, your baby would get the study vaccine and be followed for about 12 months to check safety and early signs of protection.

Siglé, Boulkiemdé Province
NCT06958198Recruiting· Phase 1
Testing a new multi-stage malaria vaccine in adults and children

This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.

Siglé, Boulkiemdé Province

Hear when a new Malaria (Plasmodium Falciparum) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.